Literature DB >> 688570

Primary hypertension refractory to triple drug treatment: a study on central and peripheral hemodynamics.

O Andersson, L Hansson, R Sivertsson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688570     DOI: 10.1161/01.cir.58.4.615

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

1.  Acute management of severe hypertension with oral labetalol.

Authors:  R R Ghose
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Effect of ibopamine on peripheral haemodynamics.

Authors:  C Longhini; G F Musacci; L Ansani; T Toselli; M Artioli; L Bianco; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Felodipine in the treatment of patients with severe hypertension and impaired renal function.

Authors:  R Larsson; M K Lindsjö; B Danielsson; U Bengtsson; J H Hardlund; P A Sjöström; D Elmfeldt; L Moberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

4.  Cardiovascular response to exercise and regional haemodynamics during treatment with prizidilol hydrochloride (SK & F 92 657) in moderately severe essential hypertension.

Authors:  O Andersson; S Ljungman; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Diuretic treatment of resistant hypertension.

Authors:  L E Ramsay; J H Silas; S Freestone
Journal:  Br Med J       Date:  1980-10-25

6.  Felodipine. A calcium-inhibiting vasodilator in refractory hypertension.

Authors:  O K Andersson; G Granérus; T Hedner
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.

Authors:  C Longhini; L Ansani; G F Musacci; S Aggio; E Baracca; T Toselli; P Ghirardi
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.